Blue Owl Capital Holdings’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-49,000
Closed -$3.57M 48
2024
Q1
$3.57M Buy
49,000
+15,000
+44% +$1.25M 0.71% 26
2023
Q4
$3.29M Buy
+34,000
New +$6.62M 0.79% 23

Other funds holding LABD

Blue Owl Capital Holdings's LABD Position: Q2 2024 in Review

Blue Owl Capital Holdings sold out of Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q2 2024, closing a stake of 49,000 shares — an estimated $3.57M sold.

Blue Owl Capital Holdings first reported a position in LABD in Q4 2023 and held it in 2 quarters. The position peaked at $3.57M in Q1 2024. 17 funds tracked by Wall St. Rank hold LABD as of Q2 2024.

  • Blue Owl Capital Holdings reported no remaining Direxion Daily S&P Biotech Bear 3X ETF position as of Q2 2024 after selling out during the quarter.
  • Blue Owl Capital Holdings sold 49,000 Direxion Daily S&P Biotech Bear 3X ETF shares in Q2 2024, an estimated $3.57M.
  • Blue Owl Capital Holdings first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q4 2023 and held it in 2 quarters.
  • Blue Owl Capital Holdings's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $3.57M in Q1 2024.
  • 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q2 2024.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2024, filed 15 Aug 2024.